Search
RO-6870810
go.drugbank.com/drugs/DB15151InvestigationalRO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Synonyms: 2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide, 6H-THIENO(3,2-F)(1,2,4)TRIAZOLO(4,3-A)(1,4)DIAZEPINE-6-ACETAMIDE, 4-(4-CHLOROPHENYL)-2,3,9-TRIMETHYL-N-(3-(4-METHYL-1-PIPERAZINYL)PROPYL)-, (6S)-Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-Urolithin A
go.drugbank.com/drugs/DB15464ExperimentalUrolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.[A179494]
Synonyms: Uro-A, Urolithin ATMC-310911
go.drugbank.com/drugs/DB15623InvestigationalTMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for … TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available [darunavir].
Sulfamethylthiazole
go.drugbank.com/drugs/DB15882ExperimentalSulfamethylthiazole is a sulfonamide antibacterial agent.[A275183]
Odevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].
Orelabrutinib
go.drugbank.com/drugs/DB16272InvestigationalOrelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered
Nutlin-3
go.drugbank.com/drugs/DB17039ExperimentalNutlin-3 is a small molecule inhibitor that targets p53-Mdm2 interaction.[A253057]